A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Segal, N. H.; Verghis, J.; Govindan, S.; Maliakal, P.; Sharkey, R. M.; Wegener, W. A.; Goldenberg, D. M.; Saltz, L. B. |
| Abstract Title: | A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC) |
| Meeting Title: | 104th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 73 |
| Issue: | 8 Suppl. |
| Meeting Dates: | 2013 Apr 6-10 |
| Meeting Location: | Washington, DC |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2013-04-15 |
| Language: | English |
| ACCESSION: | WOS:000331220601095 |
| DOI: | 10.1158/1538-7445.am2013-lb-159 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LB-159 -- 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 06-10, 2013 -- Washington, DC -- 1 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
